Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Sadelain

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
Blood|November 27, 2010
RORing T cells target CLL and MCLMichel Sadelain
The Journal of Clinical Investigation|September 2, 2015
CAR therapy: the CD19 paradigmMichel Sadelain
Cancer Journal (Sudbury, Mass.)|December 17, 2009
T-cell engineering for cancer immunotherapyMichel Sadelain
The New England Journal of Medicine|November 4, 2011
Eliminating cells gone astrayMichel Sadelain
Current Opinion in Immunology|July 4, 2016
Chimeric antigen receptors: driving immunology towards synthetic biologyMichel Sadelain
Cancer Investigation|February 10, 2006
The meaning of translationMichel Sadelain
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 9, 2016
A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome EditingMichel Sadelain
Current Opinion in Hematology|March 29, 2006
Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemiaMichel Sadelain
The Journal of Gene Medicine|April 5, 2002
Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapyMichel Sadelain
Cancer Journal (Sudbury, Mass.)|March 27, 2014
From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. IntroductionMichel Sadelain
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
Blood|November 27, 2010
RORing T cells target CLL and MCLMichel Sadelain
The Journal of Clinical Investigation|September 2, 2015
CAR therapy: the CD19 paradigmMichel Sadelain
Cancer Journal (Sudbury, Mass.)|December 17, 2009
T-cell engineering for cancer immunotherapyMichel Sadelain
The New England Journal of Medicine|November 4, 2011
Eliminating cells gone astrayMichel Sadelain
Current Opinion in Immunology|July 4, 2016
Chimeric antigen receptors: driving immunology towards synthetic biologyMichel Sadelain
Cancer Investigation|February 10, 2006
The meaning of translationMichel Sadelain
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 9, 2016
A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome EditingMichel Sadelain
Current Opinion in Hematology|March 29, 2006
Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemiaMichel Sadelain
The Journal of Gene Medicine|April 5, 2002
Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapyMichel Sadelain
Cancer Journal (Sudbury, Mass.)|March 27, 2014
From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. IntroductionMichel Sadelain
Pageof 27